Avalo Therapeutics (AVTX) announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa. The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enrolled. Topline data from the trial is expected in mid-2026. “The completion of enrollment in the LOTUS trial marks another important milestone in our AVTX-009 program,” said Dr. Garry Neil, Chief Executive Officer. “We are encouraged by the strong investigator and patient engagement in this trial, which reflects the high unmet need that exists for people living with HS. With AVTX-009’s high-affinity inhibition of IL-1beta, we believe we are one step closer to offering a differentiated, potentially best-in-disease, treatment option for patients suffering from this chronic and painful condition.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study
- Oppenheimer healthcare analysts hold an analyst/industry conference call
- Avalo Therapeutics management to meet with Piper Sandler
- Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation
- Avalo Therapeutics Strengthens Leadership with Key Appointments